Leading Indian drug makers have sharply increased their R&D budgets over the past five years, as they stare at tempered growth in the US from the launch of plain generics. The R&D spending of the top seven Indian drug makers rose to around Rs 8,500 crore in the last fiscal year from Rs 2,700 crore in fiscal 2011, according to one estimate.

Experts predict the launch pipelines for generic players in the US will be impacted as drugs coming off patent may see a fall in the 2017-2020 period. Amid gloomy outlooks of weakening growth in the large markets of the US and Europe and competition-induced price erosion, Indian companies are focusing on the development of complex drugs to offset the impact.

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/top-pharma-firms-hike-complex-drug-rd-spend-to-rs-8500-crore-in-2015-16-eye-buyouts/articleshow/56028235.cms

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *